相关实验视频
Updated: Jun 27, 2025
04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
442
在液体冷凝剂中抑制α-synuclein聚合的药理抑制
Samuel T Dada1, Zenon Toprakcioglu1, Mariana P Cali1
1Department of Chemistry, Centre for Misfolding Disease, University of Cambridge, Cambridge, CB2 1EW, UK.
Nature communications
|May 7, 2024
概括
小分子可以抑制与帕金森病相关的α-synuclein聚合. 化合物克拉胺稳定了α-synuclein凝聚物,为神经退行性疾病提供了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
背景情况:
- 帕金森病的特征是Lewy体,主要由聚合的α-synuclein组成.
- 新兴研究表明,α-synuclein聚合可能起源于液态到固态相变的过程中,形成蛋白质凝结物.
- 这种相分离机制为帕金森病的治疗干预提供了新的途径.
研究的目的:
- 为了研究小分子在抑制由凝聚驱动的α-synuclein聚合的潜力.
- 为了确定特定的化合物,可以调节液体凝聚物内的α-synuclein聚合.
- 探索帕金森病的新疗法策略,通过准凝结物中的蛋白质聚合.
主要方法:
- 使用体外和Caenorhabditis elegans模型来研究α-synuclein聚合.
- 采用化学动力学方法来阐明候选抑制剂的作用机制.
- 对小分子进行选,以确定它们稳定α-synuclein凝聚物和抑制聚合的能力.
主要成果:
- 证明小分子可以有效地抑制alpha-synuclein的凝结驱动的聚合途径.
- 确定了aminosterol claramine作为一种稳定α-synuclein凝聚物的化合物,并抑制聚合.
- 确定克拉拉胺通过抑制缩物中的初级核形成而起作用.
结论:
- 通过小分子介导的缩物内的α-synuclein聚合的抑制是一种可行的治疗策略.
- 克拉拉胺代表了一种有希望的化合物,用于开发帕金森病的治疗方法.
- 针对凝聚物中的蛋白质聚合可能为各种神经退行性疾病提供更广泛的治疗方法.
相关概念视频
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
554
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
554
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:26Neurochemical Transmission: Sites of Drug Action
2.2K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
2.2K